Your browser doesn't support javascript.
loading
Immune Checkpoint Inhibitor Cardiotoxicity: Understanding Basic Mechanisms and Clinical Characteristics and Finding a Cure.
Waliany, Sarah; Lee, Daniel; Witteles, Ronald M; Neal, Joel W; Nguyen, Patricia; Davis, Mark M; Salem, Joe-Elie; Wu, Sean M; Moslehi, Javid J; Zhu, Han.
Afiliação
  • Waliany S; Department of Medicine, Stanford University, Stanford, California 94305, USA; email: hanzhu@stanford.edu.
  • Lee D; Stanford Cardiovascular Institute, Stanford University, Stanford, California 94305, USA.
  • Witteles RM; Department of Medicine, Stanford University, Stanford, California 94305, USA; email: hanzhu@stanford.edu.
  • Neal JW; Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, California 94305, USA.
  • Nguyen P; Department of Medicine, Stanford University, Stanford, California 94305, USA; email: hanzhu@stanford.edu.
  • Davis MM; Division of Oncology, Stanford University School of Medicine, Stanford, California 94305, USA.
  • Salem JE; Department of Medicine, Stanford University, Stanford, California 94305, USA; email: hanzhu@stanford.edu.
  • Wu SM; Stanford Cardiovascular Institute, Stanford University, Stanford, California 94305, USA.
  • Moslehi JJ; Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, California 94305, USA.
  • Zhu H; Department of Microbiology and Immunology and Howard Hughes Medical Institute, Stanford University School of Medicine, Stanford, California 94305, USA.
Annu Rev Pharmacol Toxicol ; 61: 113-134, 2021 01 06.
Article em En | MEDLINE | ID: mdl-32776859
Immune checkpoint inhibitors (ICIs) attenuate mechanisms of self-tolerance in the immune system, enabling T cell responses to cancerous tissues and revolutionizing care for cancer patients. However, by loweringbarriers against self-reactivity, ICIs often result in varying degrees of autoimmunity. Cardiovascular complications, particularly myocarditis but also arrhythmias, pericarditis, and vasculitis, have emerged as significant complications associated with ICIs. In this review, we examine the clinical aspects and basic science principles that underlie ICI-associated myocarditis and other cardiovascular toxicities. In addition, we discuss current therapeutic approaches. We believe a better mechanistic understanding of ICI-associated toxicities can lead to improved patient outcomes by reducing treatment-related morbidity.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Sistema Cardiovascular / Miocardite / Neoplasias Tipo de estudo: Diagnostic_studies Limite: Humans Idioma: En Revista: Annu Rev Pharmacol Toxicol Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Sistema Cardiovascular / Miocardite / Neoplasias Tipo de estudo: Diagnostic_studies Limite: Humans Idioma: En Revista: Annu Rev Pharmacol Toxicol Ano de publicação: 2021 Tipo de documento: Article